It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...

Company to host conference call today at 4:30 p.m. EDT LAUSANNE, Switzerland, June 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced topline ...

Prince Edward Island farmers made significantly less money in 2025 as a historic drought reduced revenues and rising expenses ...

Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...

Absence of a scalp-specific cancer excess challenges the UV-exposure hypothesis and supports maintaining standard, individualized skin cancer risk assessment rather than AA-specific screening ...

Explore XMMO’s buy case: mid-cap momentum ETF returns, AI/semiconductor drivers, valuation risks, and why pairing with XMHQ ...

The combination of pharmacotherapy and psychotherapy is associated with reductions in emergency department visits and inpatient admissions along with lower total cost of care relative to either ...

After the sponsor halted the trial, despite the DSMB’s advice to continue, investigators aimed to salvage the scientific value.

US indices look to rally again on Wednesday in what has been a very strong move higher for some time. With this, I think you ...

Since returning to power in January 2025, the Mahama administration has moved with unusual speed and ambition on the question ...

People with comorbid alcohol use disorder and obesity may represent a distinct clinical subgroup, with glucose dysregulation ...

Artificial intelligence (AI) increasingly influences clinical decision-making, yet its recommendations may diverge from standard care. Although malpractice concerns are thought to discourage ...